Catalyst demonstrates unwavering commitment to clients, adapting and flexing with needs
Wilmington, N.C., May 19, 2025 – Catalyst Clinical Research today announces it was named a Fierce CRO Award finalist by Fierce Biotech in the Excellence in Clinical Trial Management category.
Catalyst demonstrates unwavering commitment to our sponsors, adapting and flexing with study needs. In one study, Catalyst’s recommendations for study design changes laid the groundwork for a successful outcome. The overall clinical trial exceeded enrollment goals. Most importantly, a recent endpoint analysis indicated a potential treatment effect enabling the Sponsor to pursue a Breakthrough Therapy Designation and potential registrational submission.
The Fierce CRO Awards celebrate exceptional achievements and innovations by Contract Research Organizations (CROs). These awards honor CROs that have demonstrated outstanding performance, innovation, and leadership in delivering high-quality research and development services. By recognizing the excellence of CROs, the awards aim to highlight the critical role they play in advancing life sciences research and improving patient outcomes.
“Our teams are committed to supporting our clients to help bring new therapies to patients. It is Catalyst’s mission to deliver our best work for our clients,” says Nik Morton, President and CEO, Catalyst Clinical Research. “Catalyst is incredibly honored to receive this recognition from the Fierce CRO Awards.”
The Fierce CRO Awards finalists were judged on: Innovation and Impact, Measurable Outcomes, Sustainability and Scalability and Ethical and Regulatory Adherence.
Fierce CRO Awards winners will be announced on June 18.
About Catalyst Clinical Research
Catalyst Clinical Research, a contract research organization (CRO), provides highly customizable solutions to the global biopharmaceutical and biotechnology industries through two established, branded solutions: Catalyst Oncology and Catalyst Flex. The company provides full-service oncology CRO offerings with Catalyst Oncology and multi-therapeutic customer- or Catalyst-managed functional services through Catalyst Flex. With more than 1,000 staff and several offices in the United States, Europe, and the Asia-Pacific region, Catalyst’s flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping customers advance their clinical studies by leveraging expert teams and innovative technologies. Visit Catalyst online at CatalystCR.com. Follow @CatalystCR on LinkedIn.
Catalyst is a portfolio company of QHP Capital, a leading healthcare and life sciences investment firm.
About Fierce Biotech
Fierce Biotech is the biotech industry’s daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. Signup is free here.
